About David Miyamoto, MD, PhD

David Miyamoto, MD, PhD is an Assistant Professor of Radiation Oncology at Harvard Medical School, an attending radiation oncologist at the Massachusetts General Hospital, an Investigator in the Krantz Family Center for Cancer Research, and an Associate Member of the Broad Institute of Harvard and MIT. Dr. Miyamoto received his undergraduate degree in Chemistry from Harvard College, MD from Harvard Medical School, and PhD in Cell Biology from Harvard University. He completed his internship in Internal Medicine at the Brigham & Women's Hospital and his residency in the Harvard Radiation Oncology Program. Dr. Miyamoto is a board-certified radiation oncologist specializing in genitourinary malignancies who sees patients in the Bertucci Center for Genitourinary Cancers at the Mass General Cancer Center and the Department of Radiation Oncology. His research efforts focus on the development of novel biomarkers to guide prostate cancer and bladder cancer therapy and improve the individualized care of each patient. He has authored more than 50 publications in peer-reviewed scientific journals including Science, Cell, Lancet Oncology, and Cancer Discovery. His research has been supported by the National Cancer Institute, US Department of Defense, Prostate Cancer Foundation, Radiation Oncology Institute, and the Dana Farber/Harvard Cancer Center.

Departments, Centers, & Programs:

Clinical Interests:




Mass General Cancer Center: Radiation Oncology
55 Fruit St.
Lunder Building, LL3
Boston, MA 02114
Phone: 617-726-5866

Medical Education

  • MD, Harvard Medical School (Massachusetts)
  • Residency, Massachusetts General Hospital

American Board Certifications

  • Radiation Oncology, American Board of Radiology

Accepted Insurance Plans

Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.


The Miyamoto laboratory focuses on the discovery and development of novel biomarkers to guide the personalized treatment of patients with prostate cancer and bladder cancer. We focus on two general classes of biomarkers, namely those based on the molecular profiles of tumor biopsies, and those based on circulating tumors cells (CTCs) in the blood that can be sampled non-invasively and repeatedly. By analyzing these patient-derived specimens, we have identified new molecular predictors of response to therapy and potential mechanisms of treatment resistance. Our overall aim is to develop tools for “real-time precision medicine” to probe the molecular signatures of cancers as they evolve over time, and to guide the precise and rational selection of appropriate therapies for each individual patient with cancer.


Reviews: Comments and Ratings